• Toxicological Research
• /
• 제28권3호
• /
• pp.179-185
• /
• 2012

Paecilomyces sinclairiis (PS) is known as a functional food or human health supplement. However concerns have been raised about its kidney toxicity. This study was performed to investigate the kidney toxicity of PS by 13 week-oral administration to rats. Blood urea nitrogen (BUN), serum creatinine, and kidney damage biomarkers including beta-2-microglobulin (${\beta}2m$), glutathione S-transferase alpha (GST-${\alpha}$), kidney injury molecule 1 (KIM-1), tissue inhibitor of matrix metalloproteinase 1 (TIMP-1), vascular endothelial growth factor (VEGF), calbindin, clusterin, cystatin C, neutrophil gelatinase-associated lipocalin (NGAL) and osteopontin were measured during or after the treatment of PS. BUN, creatinine and kidney damage biomarkers in serum were not changed by PS. However, kidney cell karyomegaly and tubular hypertrophy were observed dose-dependently with higher severity in males. KIM-1, TIMP-1 and osteopontin in kidney and urine were increased dose dependently in male or at the highest dose in female rats. Increased urinary osteopontin by PS was not recovered at 2 weeks of post-exposure in both genders. Cystatin C in kidney was decreased at all treatment groups but inversely increased in urine. The changes in kidney damage biomarkers were more remarkable in male than female rats. These data indicate that the PS may provoke renal cell damage and glomerular filtration dysfunction in rats with histopathological lesions and change of kidney damage biomarkers in kidney or urine. Kidney and urinary KIM-1 and cystatin C were the most marked indicators, while kidney weight, BUN and creatinine and kidney damage biomarkers in serum were not influenced.

• 대한유전성대사질환학회지
• /
• 제12권2호
• /
• pp.99-103
• /
• 2012

I형 타이로신혈증은 타이로신의 분해 과정 중 최종단계에 관여하는 효소인 fumarylacetoacetate hydrolase(FAH)의 결핍에 의한 대사 이상질환이다. 급성 I형 타이로신혈증은 치명적인 간부전이나 혈액응고장애와 같은 급성 임상증상이 나타난 이후에는 예후가 불량하였으나 최근에는 신생아 대사이상 선별검사를 통해 조기 진단이 가능해졌고 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3 cyclohexanedione nitisinone (NTBC) 약물 치료로 타이로신혈증의 치료 성적이 향상됨에 따라 신생아 대사이사 선별검사를 통한 조기 진단과 조기 치료가 더욱 중요해졌다고 할 수 있다. 이에 저자들은 심각한 출혈이나 간부전과 같은 급성 이상 증상이 나타나기 전 신생아 대사이상 선별검사로 조기 진단 및 조기 중재적 치료로 양호한 경과를 보이고 있는 I형 타이로신혈증 1례를 경험하였기에 문헌 고찰과 함께 보고하는 바이다.

• 대한소아치과학회지
• /
• 제29권2호
• /
• pp.237-242
• /
• 2002

Lowe 증후군 또는 안뇌신증후군(oculocerebrorenal syndrome)은 X-염색체와 관련된 유전성 질환으로 반성열성유전양상을 나타낸다. 선천성 백내장과 녹내장 등의 안 증상, 근긴장 저하 건반사감소 등의 근신경계 증상, 신장 기능이상이 가장 특징적인 임상 증상이며, 이외에도 정신 지체, 성장지연, 전두부 융기, 가늘고 성긴 모발, 돌출된 귀, 골질환 등이 발생할 수 있다. Lowe 증후군 환자는 정신지체로 인해 치과치료시 전신마취하에서의 처치가 요구되나, 대사성 산증, 악성고열의 발생위험과 사용약제에 의한 부작용 등이 위험요소로 작용할 수 있으므로, 필요한 경우 내과 또는 소아과 의료진이 참여된 협진체제 하에서 가능한 짧은 시간 진행되어야 한다. 이러한 치과적 처치의 어려움으로 Lowe 증후군 환자에서 치과질환의 예방이 좀더 강조되어야 하면, 이를 위해 보호자의 주위의 적극적 관리가 요구된다.

• 대한소아치과학회지
• /
• 제39권2호
• /
• pp.161-165
• /
• 2012

Lowe syndrome은 X-염색체 반성열성 유전 질환으로 1952년 Lowe 등에 의해 처음으로 보고되었다. 대부분 남성에게 발생하며, 주요 임상증상으로는 선천성 백내장 및 녹내장 등의 안구증상, 정신지체 및 근긴장저하 등의 근신경계 증상, 신장의 기능이상 등이 있고, 정신지체에 의한 행동조절 문제로 인해 전신마취를 시행할 경우 신장 기능 저하에 따른 대사성 산증과 악성 고열 발생의 위험성이 높아진다. Lowe syndrome으로 진단된 10세 2개월 된 남아가 치석이 많고, 칫솔질이 어렵다는 것을 주소로 전남대학교 치과병원 소아치과에 내원하였다. 임상 검사 시 전반적으로 심한 치석의 침착, 법랑질 형성 부전, 변연성 치은염, 영구치의 맹출 지연, 전반적인 치아 동요 등의 소견을 보였으며, 심한 정신지체로 인해 환자의 협조도가 부족하여 진정요법 하에 외래에서 치과치료를 시행하였다. 행동조절의 어려움과 전신마취시의 위험성, 대사장애 처치에 사용되는 각종 약물로 인한 치아착색과 치석형성의 용이함 때문에 Lowe syndrome 환아의 치과적 관리는 특히 예방에 중점을 두어야 한다.

• 대한임상독성학회지
• /
• 제15권2호
• /
• pp.122-130
• /
• 2017

Purpose: To evaluate the effects of low-dose intravenous N-acetylcysteine on the prevention of contrast-induced nephropathy (CIN) in patients undergoing computed tomography (CT). Methods: All patients presenting to our emergency department and undergoing CT with intravenous contrast media between August 2014 and April 2016 were retrospectively enrolled. We included hospitalized patients with renal dysfunction [estimated glomerular filtration rate (GFR) between 30 and $89mL/min/1.73m^2$]. A 600-mg injection of N-acetylcysteine was given to patients once before and once immediately after CT, depending on the preference of physician. The primary outcome was CIN defined as an increase in creatinine level of ${\geq}25%$ or ${\geq}0.5mg/dL$ from the baseline within 48 to 72 hours after CT. A trained person blindly reviewed all medical records. Results: Of the 1903 admitted patients, CIN occurred in 9.8% of patients who received 1200 mg intravenous N-acetylcysteine (24/244) and 6.8% of patients who did not (113/1659, p=0.090). In a multivariable regression analysis, N-acetylcystine was not relevant to the prevention of CIN (odds ratio=1.42 [95% CI, 0.90-2.26]). Even in the stratified analysis using the propensity score matching, N-acetylcysteine was irrelevant (GFR 30-59: odds ratio=1.06 [95% CI, 0.43-2.60]; GFR 60-89: odds ratio=1.76 [95% CI, 0.75-4.14]). After adjustment, crystalloids were significantly associated with the reduction in CIN compared with dextrose water (odds ratio=0.60 [95% CI, 0.37-0.97]). Conclusion: No effect was found when low-dose intravenous N-acetylcysteine was used to prevent CIN. However, there seems to be an association between crystalloids and reduction in CIN.

• 한국임상약학회지
• /
• 제12권1호
• /
• pp.13-21
• /
• 2002

After the introduction of cyclosporin, the graft survival rate of renal transplant and patients' life expectancy have been greatly improved. However, cyclosporin is known to cause several undesirable side effects, one of which is hyperuricemia, which may subsequently cause gouty nephropathy and graft dysfunction. The purpose of this study was to evaluate the frequency and predisposing factors of hyperuricemia in cyclosporin-treated patients within one year of kidney transplantation and uricosuric efficacy of benzbromarone. The patients who were treated with cyclosporin after kidney transplantation in 1998 and the patients who were treated with benzbromarone for the control of cyclosporin-induced hyperuricemia in 1999 were investigated retrospectively. Among the 76 patients in cyclosporin-treated patients in 1998, hyperuricemia occurred in 55 patients $(72.4\%)$ and the mean time from kidney transplantation to occurrence of hyperuicemia was $5.0\pm8.0$ months. In 1999, 22 patients were treated with benzbromarone for hyperuricemia and their mean time from kidney transplantation to occurrence of hyperuricemia was $4.5\pm10.4$ months. Acute rejection developed in one patient $(4.8\%)$ out of 21 normo-uricemic patients and 11 patients $(20.0\%)$ out of 55 hyperuricemic patients in 1998. The difference of rejection rate in these two groups was significant (p<0.001). There was no difference of rejection rate between before and after treatment of benzbromarone. Cyclosporin trough levels did not show a significant correlation with the serum uric acid levels among the three groups. However, hyperuricemic patients showed significantly higher serum creatinine levels than patients with normal uric acid levels (p<0.001). Benzbromarone decreased serum uric acid levels from $8.3\pm2.3\;mg/dl\;to\;5.1\pm2.0\;mg/dl$ (p<0.0001) and normalizing serum uric acid in all of 22 patients. Except for one patient $(4.5\%)$ who experienced diarrhea, no significant side effect was noted.

• The Korean Journal of Physiology and Pharmacology
• /
• 제24권5호
• /
• pp.403-412
• /
• 2020

Diabetic nephropathy (DN) is a hyperglycemia-induced progressive development of renal insufficiency. Excessive glucose can increase mitochondrial reactive oxygen species (ROS) and induce cell damage, causing mitochondrial dysfunction. Our previous study indicated that cilostazol (CTZ) can reduce ROS levels and decelerate DN progression in streptozotocin (STZ)-induced type 1 diabetes. This study investigated the potential mechanisms of CTZ in rats with DN and in high glucose-treated mesangial cells. Male Sprague-Dawley rats were fed 5 mg/kg/day of CTZ after developing STZ-induced diabetes mellitus. Electron microscopy revealed that CTZ reduced the thickness of the glomerular basement membrane and improved mitochondrial morphology in mesangial cells of diabetic kidney. CTZ treatment reduced excessive kidney mitochondrial DNA copy numbers induced by hyperglycemia and interacted with the intrinsic pathway for regulating cell apoptosis as an antiapoptotic mechanism. In high-glucose-treated mesangial cells, CTZ reduced ROS production, altered the apoptotic status, and down-regulated transforming growth factor beta (TGF-β) and nuclear factor kappa light chain enhancer of activated B cells (NF-κB). Base on the results of our previous and current studies, CTZ deceleration of hyperglycemia-induced DN is attributable to ROS reduction and thereby maintenance of the mitochondrial function and reduction in TGF-β and NF-κB levels.

• 대한한방내과학회지
• /
• 제22권2호
• /
• pp.245-250
• /
• 2001

Paraquat is one of the widely used herbicides. But it is fatal, if it is consumed by people. Paraquat poisoning causes acute renal failure, hepatic dysfunction, and progressive respiratory failure. There are no effective antidotes to paraquat. This report is about one case's treatment for acute hepatitis caused by paraquat. The patient was hospitalized in the Department of Internal Medicine, Wonkwang University Oriental Medical Hospital in Chonju. The patient received the following treatments while in an acute stage : Gamdutanggamibang(甘豆湯加味方), which consists of Radix glycyrrhizae(甘草), Semen mungo(綠豆), burned powder of Rhizoma rhei(大黃炒炭末), Succus phyllostachyos(竹瀝), chinese ink(墨汁) and fluid therapy. The patient received Sagunjatanggamibang(四君子湯加味方) while in a chronic stage. The patient improved faster with the above treatments than with the conventional treatment. We hope that this report will help widening the clinical range of oriental medicine, and improve systemic efforts in treating paraquat poisoning cases.

• Journal of Dental Anesthesia and Pain Medicine
• /
• 제19권4호
• /
• pp.181-189
• /
• 2019

Local anesthetic systemic toxicity (LAST) refers to the complication affecting the central nervous system (CNS) and cardiovascular system (CVS) due to the overdose of local anesthesia. Its reported prevalence is 0.27/1000, and the representative symptoms range from dizziness to unconsciousness in the CNS and from arrhythmias to cardiac arrest in the CVS. Predisposing factors of LAST include extremes of age, pregnancy, renal disease, cardiac disease, hepatic dysfunction, and drug-associated factors. To prevent the LAST, it is necessary to recognize the risk factors for each patient, choose a safe drug and dose of local anesthesia, use vasoconstrictor, confirm aspiration and use incremental injection techniques. According to the treatment guidelines for LAST, immediate application of lipid emulsion plays an important role. Although lipid emulsion is commonly used for parenteral nutrition, it has recently been widely used as a non-specific antidote for various types of drug toxicity, such as LAST treatment. According to the recently published guidelines, 20% lipid emulsion is to be intravenously injected at 1.5 mL/kg. After bolus injection, 15 mL/kg/h of lipid emulsion is to be continuously injected for LAST. However, caution must be observed for >1000 mL of injection, which is the maximum dose. We reviewed the incidence, mechanism, prevention, and treatment guidelines, and a serious complication of LAST occurring due to dental anesthesia. Furthermore, we introduced lipid emulsion that has recently been in the spotlight as the therapeutic strategy for LAST.

• Journal of Medicine and Life Science
• /
• 제17권3호
• /
• pp.80-85
• /
• 2020

Urinary tract infections are among the most common infectious diseases and are the major causes of mortality and morbidity. These diseases result in many severe hospitalizations each year. Severe sepsis and septic shock are common and life-threatening medical conditions, and large cases are associated with urinary tract infection. The medical term "severe sepsis" is defined as sepsis complicated by hypotension, organ dysfunction, and tissue hypoperfusion, whereas "septic shock" is defined as sepsis complicated either by hypotension that is refractory to fluid resuscitation or by hyperlacteremia. A recent multicenter-study in Korea reported that the rate of in-hospital mortality associated with severe sepsis and septic shock was > 34%. Among the causative diseases, urogenital tract infection showed a high correlation. Moreover, it is very important that clinicians detect severe sepsis and septic shock early and treat them properly. The principles of initial treatment include provision of sufficient hemodynamic resuscitation and early administration of appropriate antibiotic therapy to mitigate uncontrolled infection. Initial resuscitation includes the use of vasopressors and intravenous fluids, and it is a key to achieve the target of initial resuscitation. Supportive care in the intensive care unit, such as glucose control, stress ulcer prophylaxis, blood transfusion, deep vein thrombosis prophylaxis, and renal replacement therapy, is also significant. We have summarized the key components in the treatment of severe sepsis and septic shock in patients with urinary tract infection. Urologists should be aware that appropriate early treatment is necessary to prevent fatal outcomes in these patients.